Ascletis Pharma (HKSE:01672) Equity-to-Asset : 0.94 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ascletis Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$2,561.70 Mil. Ascletis Pharma's Total Assets for the quarter that ended in Dec. 2023 was HK$2,724.61 Mil. Therefore, Ascletis Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.94.

The historical rank and industry rank for Ascletis Pharma's Equity-to-Asset or its related term are showing as below:

HKSE:01672' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51 Med: 0.96 Max: 0.97
Current: 0.94

During the past 8 years, the highest Equity to Asset Ratio of Ascletis Pharma was 0.97. The lowest was 0.51. And the median was 0.96.

HKSE:01672's Equity-to-Asset is ranked better than
93.33% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:01672: 0.94

Ascletis Pharma Equity-to-Asset Historical Data

The historical data trend for Ascletis Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Equity-to-Asset Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

0.97

0.96

0.94

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial										0.96	0.96	0.96	0.97	0.94

Competitive Comparison of Ascletis Pharma's Equity-to-Asset

For the Biotechnology subindustry, Ascletis Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Equity-to-Asset falls into.

Ascletis Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ascletis Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2561.702	/	2724.613
	=	0.94

Ascletis Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	2561.702	/	2724.613
	=	0.94

Ascletis Pharma (HKSE:01672) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Ascletis Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma (HKSE:01672) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

ASCLF:USA

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.

Executives

Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines